Clinical Neuroscience

[Measuring of functional impairment of lumbal spine]

VALASEK Tamás1, VARGA Péter Pál2, KLEMENCSICS István2, SZÖVÉRFI Zsolt2, BOZSÓDI Árpád, ÉLTES Péter Endre2, LAZÁRY Áron2

MARCH 25, 2015

Clinical Neuroscience - 2015;68(03-04)

[Background and purpose - The purpose of our study was to outline the Hungarian validation process of the Oswestry Disability Index, the Quebec Back Pain Disability Scale, the Roland-Morris Disability Questionnaire and the Core Outcome Measurement Index, as well as to draw up recommendations regarding their future applications. Methods - The Hungarian versions were brought to life after a cultural and linguistic adaptation. Next to the above-mentioned questionnaires, the questionnaire booklet used for validation also contained the WHOQoL-BREF general quality of life questionnaire and a pain measuring Visual Analog Scale. The data of low-back pain patients were registered twice in two weeks. We determined the internal homogeneity (Cronbach alpha), reproducibility, standard error of measurement and the minimal detectable change of the questionnaires. Patients were assigned into different two subgroups (surgical / non-surgical, with / without affection of nerve roots) and differences between the subgroups were examined with the help of the questionnaires. We determined the physical subscale of the WHOQoL-BREF and the correlation between the pain and the studied questionnaires. Results - The value of Cronbach alpha was between 0.85 and 0.95. All four questionnaires showed significant differences (p<0.001) between the subgroups. The correlation studies brought strong and significant results (p<0.001, r>0.5) in every case. The values of reproducibility were between 0.93-0.92. The results of standard measurement error: 4.8 (Oswestry), 5.2 (Quebec), 1.6 (Roland-Morris), 0.59 (Core Index). The minimal detectable change was 13; 14; 4, and 2 points, respectively. Conclusion - The Hungarian versions of all four questionnaires are valid. They can be applied with scientific certainty to measure low back pain patients. From the studied questionnaires, we especially recommend the wide-raging application of the Oswestry Disability Index and the Core Outcome Measurement Index based on their psychometric and application features. ]

AFFILIATIONS

  1. Semmelweis Egyetem, Egészségtudományi Kar, Alapozó Egészségtudományi Intézet, Budapest
  2. Országos Gerincgyógyászati Központ, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[Help! Accumulation of manuscripts!]

TAJTI János, RAJNA Péter

Clinical Neuroscience

[Teriflunomide: new oral immunmodulant drug in therapy of multiple sclerosis]

BENCSIK Krisztina, RÓZSA Csilla, VÉCSEI László

[Multiple sclerosis (MS) is the autoimmune, demyelinating, neurodegenerative disorder of the central nervous system (CNS). There are nine drugs available in Hungary reimbursed by the National Health Insurance Fund of Hungary (OEP) to reduce the activity of the disease, from which seven can be used as first line therapies. We have approximately 20 years of experience with the interferon b-1a/1b and glatiramer-acetate products. Though in case of approximately 30% of the patients using one of the first line drugs, the disease remains active, that we call break-through disease. The reasons for break-through disease could be the insufficient adherence and compliance, the appearance of neutralizing antibodies or the high activity of the disease. One of the oral immunomodulating drugs for MS, teriflunomide, was registered in Europe in 2013. Because of the anti-proliferative and anti-inflammatory effect of teriflunomide, it can be used for the reduction of the disease activity in the relapsing-remitting course of MS. The effect of teriflunomide was proved in one Phase II. and four Phase III. (TEMSO, TOWER, TENERE, TOPIC) studies. Teriflunomide 14 mg once daily was able to demonstrate in two consecutive placebo-controlled phase 3 clinical trials that significantly reduces the relapse rate (31.5% and 36.3%) and in both studies significantly reduces the sustained disability progression (29.8% and 31.5%) moreover delays the appearance of the clinically definitive MS in patients with clinically isolated syndrome (CIS). According to the TENERE study there were no significant differences observed between teriflunomide 14 mg and IFNb-1a s.c. in time to failure and annualized relapse rate but the treatment satisfaction domains of global satisfaction, side-effects and convenience were significantly improved with teriflunomide compared with s.c. IFNb-1a. ]

Clinical Neuroscience

[Proconvulsive effect of antiepileptic drugs]

KELEMEN Anna

[Antiepileptic drugs can provoke and worsen seizures, what is called paradoxical effect. Paradoxical seizure worsening can occur as a nonspecific manifestation of drug intoxication in number of antiepileptic drugs. The other type is a specific type, when antiepileptic drugs with pure GABAergic and sodium channel blocker mechanism of action provoke myoclonic, absence and atonic seizures in specific epilepsy syndromes, mainly in idiopathic generalized epilepsies. Antiepileptic drug-induced exacerbation of seizures is a common, often unrecognized clinical problem, which can be avoided by a careful syndromic diagnosis and by using broad spectrum antiepileptic drugs.]

Clinical Neuroscience

[Drug therapy of neuropathic pain in mirror of latest reccommandations]

KISS Gábor

[Neuropathic pain is considered as a special type of different pain conditions. It’s pathophysiological basis and treatment is completely different from the nociceptive pain. The first comprehensive therapeutic guidelines published approximately a decade ago recommended tricyclic antidepressants, anticonvulsants and opioids. The recent summary presents and evaluates national and international guidelines issued in the last five years. The most frequently suggested drugs by all guidelines are amitriptyline, duloxetine, gabapentin and pregabalin. Pregabalin is the only drug that is recommended first line in all guidelines referred. Opioids are in the second or third line. There seems to be no major development in the pharmacological treatment of the neuropathic pain compared to the earlier recommendations. High quality studies of head to head comparisons and effectiveness of combination therapy are still lacking.]

Clinical Neuroscience

[Do previous offences predict violent acts in psychiatric patients? A retrospective study in Hungary]

BARAN Brigitta, SZABÓ Ádám Ferenc, KARA Borbála, KOVÁCS Magdolna, UZONYI Adél, ANTAL Albert, UNGVARI S Gabor, GAZDAG Gábor

[Aim - To investigate the presence of offences in the previous past history of perpetrators of violent acts who have undergone forced medical treatment. Methods - The documentation of all patients released over a 10-year period from the National Institute of Forensic Psychiatry (IMEI) was reviewed. A comparison was drawn between patients who were convicted of any type of offense before the violent act (patients with previous offences-PPO) and those who were not (patients with no previous offences-PNO). Results - Eighty-six (29%) and 208 (71%) patients formed the PPO and PNO groups, respectively. Prior contact with psychiatric services was significantly higher in the PPO group (p=0.038) and this group was also more likely to offend under the influence of a psychoactive substance (p<0.001). Exceptional brutality and other qualifying factors were more frequent in the PNO group (p=0.019). Conclusion - As IMEI is the only forensic institution in Hungary, the picture presented here reflects the situation in the entire country. A recidivism rate of 29% is within the internationally published range. ]

All articles in the issue

Related contents

Clinical Oncology

[Biomarkers - today and tomorrow]

KOPPER László

[Biomarkers (tumor markers in oncology) are able to make exact, objective and reproducible distinction between two groups. Biomarkers can serve different purposes, as to estimate the patient’s survival without treatment (prognostic marker), to select those patients who would respond optimally to treatment (predictive marker), to follow the patient in order to detect of a relapse (monitoring marker), helping identifi cation the tumor-type (diagnostic marker). The main task for a biomarker is to find the best treatment with less toxicity. The main enemy of biomarkers is the heterogeneity of the tumor, the continuous change in its geno- and phenotype, which can explain the low sensitivity and specifi city. More attention should be given to standardization and validity. It is highly possible, that biomarker-panel as well as marker-based clinical trials will be used in the near future.]

Lege Artis Medicinae

[The new British recommendations for the treatment of lower back pain on the basis of the new NICE guidelines - comparison with the Hungarian therapeutic practice]

VERECKEI Edit, PALKONYAI Éva, SIMONCSICS Eszter, APÁTHY Ágnes, TEMESVÁRI I. Péter

[The new NICE guidelines on lower back pain emphasise the importance of clinical assessment. Radiological imaging methods are used primarily to exclude severe diseases, such as tumour, infection, trauma or inflammation. It’s crucial to inform patients and encourage them to use self-management and stay active. Pain management is guided by the analgesic ladder. A complex physical and psychological treatment is used, which involves a structured exercise programme, manual therapy and acupuncture, taking into account the preferences of the patient. Depending on the aetiology, surgical intervention should be considered in therapy-resistant cases. Finally, the authors compare the above guidelines with the Hungarian practice in this field.]

Lege Artis Medicinae

[The validation of a disease specific quality of life instrument in patients with psoriatic arthritis]

LOVAS Kornélia, KOÓ Éva, WHALLEY Diane, MCKENNA Stephen, MEADS David, KALÓ Zoltán

[Measuring quality of life (QoL) has a growing importance in the field of health technology assessment. It is especially true for chronic diseases, such as psoriatic arthritis, which has significant impact on patients’ quality of life through the intensity of symptoms and the duration of the disease. The quality of life measurement can only be reliable and valid if an appropriate instrument is used. One of the most critical elements of the validity of quality of life intruments is the method used for adapting the questionnaire to foreign languages. Authors present their results and experience in the Hungarian adaptation of the Psoriatic Arthritis Quality of Life (PSAQoL) questionnaire.]

Clinical Neuroscience

Independent validation of the Quality of Life in Essential Tremor Questionnaire (QUEST)

KOVÁCS Márton, MAKKOS Attila, JANSZKY József, KOVÁCS Norbert

Quality of Life in Essential Tremor Questionnaire (QUEST) was specially developed for essential tremor population to measure the health-related quality of life. Besides the development of the Hungarian version, we performed an independent testing of the scale adding further information on its clinimetric properties. In this study 133 ET patients treated at University of Pécs, Hungary, were enrolled. Besides QUEST, we assessed Patient’s Global Impression-Severity (PGI-S) and Fahn-Tolosa-Marin Tremor Rating Scales. After the independent validation in accordance to the Classic Theory of Tests, we evaluated cut-off values for detecting clinically meaningful ET-related disabilities based on receiver operating characteristics analysis. Cronbach’s a was 0.897. QUEST demonstrated high convergent validity with PGI and divergent validity with disease-duration, positive family history, need for deep brain stimulation surgery, and the presence of depression and anxiety. Presence of moderate ET-related disabilities was identified by scores > 11.25 points on QUEST-SI (sensitivity: 77.4%, specificity: 83.3%); whereas scores > 20.35 points indicated severe ET-related disabilities (sensitivity: 83.3%, specificity: 59.1%). We demonstrated that the fundamental clinimetric properties of the QUEST are satisfactory.

Lege Artis Medicinae

[DISEASES OF THE SPINE ACCOMPANIED BY LOWER BACK PAIN]

TÓTH Edit Ágnes

[It is estimated that 80% of the adult population consult their general practitioner for lower back pain at some point in their life. Apart from family doctors all medical specialists may encounter this complaint, which makes the wide-spread knowledge of this topic desirable. Pain associated with spinal diseases has two distinct types, non-inflammatory and inflammatory pain. Non-inflammatory diseases may cause moderate pain that increases with movement or functional limitation lasting for a few days, other times cause a pain pattern of varying intensity that radiates to the lower extremities and is accompanied by neurological symptoms, more rarely, present as cauda equina syndrome. In most cases, the underlying cause of the symptoms is a degenerative disorder of the spine. Spinal pain of inflammatory origin, on the other hand, is characterized by pain that worsens at night, characteristically narrowed mobility, changes in the skin, mucous membranes and joints, and sometimes fever or bad general condition. This type of pain is primarily caused by seronegative spondyloarthritis or, rarely, various pyogenic or non-pyogenic bacterial infections. Management of lower back pain aims to cease pain and restore function. These are achieved by unloading, medical pain relief, antiinflammatory drugs, muscle relaxants and antidepressants, as well as physiotherapy. In special cases the administration of other drugs (e.g., antibiotics) may be necessary along with pain relief. In seronegative spondyloarthritis traditional approaches will hopefully be supplemented by biological therapy in the future. This review of recently published results on spinal diseases accompanied by lower back pain will possibly help doctors in state-of-the art care of their patients.]